Flexion's Zilretta Poised For Market Of Diabetics With Knee Pain

Flexion Therapeutics Inc. sees a role for its extended-release steroid Zilretta in serving the large subpopulation of diabetics with knee pain, following approval by the US FDA for managing osteoarthritis pain in the knee with labeling addressing this segment of the market.

Developed with Flexion's microsphere technology, Zilretta (FX006) is an intra-articular injection that combines the corticosteroid triamcinolone acetonide with a poly lactic-co-glycolic acid matrix to provide extended pain relief over 12 weeks – whereas steroid injections typically last for two to four weeks